

Section: [6. Anti-infective medicines](#) > [6.2. Antibacterials](#) > [6.2.3. Reserve group antibiotics](#)

EMLc

Codes ATC: [J01DI02](#)

Indication	Other specified bacterial diseases <span>Code ICD11: <a href="#">1C4Y</a></span>
INN	Ceftaroline fosamil
Type de médicament	Chemical agent
Groupes d'antibiotiques	<span>R</span> RESERVE
Type de liste	Liste complémentaire (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection ; 600 mg in vial (as fosamil) powder for injection
Historique des statuts LME	Ajouté pour la première fois en 2017 ( <a href="#">TRS 1006</a> ) Retiré en 2019 ( <a href="#">TRS 1021</a> )
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Lire la suite <a href="#">sur les brevets.</a>
Wikipédia	<a href="#">Ceftaroline</a>
DrugBank	<a href="#">Ceftaroline (Ceftaroline fosamil)</a>

### Résumé des preuves et recommandation du comité d'experts

With regard to the EML listing of antibiotics, the Committee endorsed revised criteria for the inclusion of Reserve group antibiotics on the Model List. Namely, Reserve group antibiotics should be included individually on the Model List when they have a favourable benefit-risk profile and proven activity against “Critical Priority” or “High Priority” pathogens as identified by the WHO Priority Pathogens List, most notably carbapenem resistant Enterobacteriaceae. Subsequently, the Committee recommended the removal of aztreonam, fourth- and fifth-generation cephalosporins (as classes), tigecycline and daptomycin from the EML and EMLc as these antibiotics did not meet the revised criteria for inclusion on the Model Lists as individual Reserve group agents.

